Re-irradiation for recurrent gliomas: Treatment outcomes and prognostic factors

Jeongshim Lee, Jaeho Cho, Jong Hee Chang, Chang Ok Suh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: The aim of this study was to evaluate the efficacy of re-irradiation in patients with recurrent gliomas and to identify subgroups for whom re-irradiation for recurrent gliomas is most beneficial. Materials and Methods: We retrospectively reviewed 36 patients with recurrent or progressive gliomas who received re-irradiation between January 1996 and December 2011. Re-irradiation was offered to recurrent glioma patients with good performance or at least 6 months had passed after initial radiotherapy (RT), with few exceptions. Results: Median doses of re-irradiation and initial RT were 45.0 Gy and 59.4 Gy, respectively. The median time interval between initial RT and re-irradiation was 30.5 months. Median overall survival (OS) and the 12-month OS rate were 11 months and 41.7%, respectively. In univariate analysis, Karnofsky performance status (KPS) ≥70 (p<0.001), re-irradiation dose ≥45 Gy (p=0.040), and longer time interval between initial RT and re-irradiation (p=0.040) were associated with improved OS. In multivariate analysis, KPS (p=0.030) and length of time interval between initial RT and re-irradiation (p=0.048) were important predictors of OS. A radiographically suspected mixture of radiation necrosis and progression after re-irradiation was seen in 5 patients. Conclusion: Re-irradiation in conjunction with surgery could be a salvage treatment for selected recurrent glioma patients with good performance status and recurrence over a long time.

Original languageEnglish
Pages (from-to)824-830
Number of pages7
JournalYonsei medical journal
Volume57
Issue number4
DOIs
Publication statusPublished - 2016 Jul

Fingerprint

Glioma
Radiotherapy
Karnofsky Performance Status
Survival
Re-Irradiation
Salvage Therapy
Necrosis
Multivariate Analysis
Survival Rate
Radiation
Recurrence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{163970cbdc714727bb27057afbc2d6c7,
title = "Re-irradiation for recurrent gliomas: Treatment outcomes and prognostic factors",
abstract = "Purpose: The aim of this study was to evaluate the efficacy of re-irradiation in patients with recurrent gliomas and to identify subgroups for whom re-irradiation for recurrent gliomas is most beneficial. Materials and Methods: We retrospectively reviewed 36 patients with recurrent or progressive gliomas who received re-irradiation between January 1996 and December 2011. Re-irradiation was offered to recurrent glioma patients with good performance or at least 6 months had passed after initial radiotherapy (RT), with few exceptions. Results: Median doses of re-irradiation and initial RT were 45.0 Gy and 59.4 Gy, respectively. The median time interval between initial RT and re-irradiation was 30.5 months. Median overall survival (OS) and the 12-month OS rate were 11 months and 41.7{\%}, respectively. In univariate analysis, Karnofsky performance status (KPS) ≥70 (p<0.001), re-irradiation dose ≥45 Gy (p=0.040), and longer time interval between initial RT and re-irradiation (p=0.040) were associated with improved OS. In multivariate analysis, KPS (p=0.030) and length of time interval between initial RT and re-irradiation (p=0.048) were important predictors of OS. A radiographically suspected mixture of radiation necrosis and progression after re-irradiation was seen in 5 patients. Conclusion: Re-irradiation in conjunction with surgery could be a salvage treatment for selected recurrent glioma patients with good performance status and recurrence over a long time.",
author = "Jeongshim Lee and Jaeho Cho and Chang, {Jong Hee} and Suh, {Chang Ok}",
year = "2016",
month = "7",
doi = "10.3349/ymj.2016.57.4.824",
language = "English",
volume = "57",
pages = "824--830",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "4",

}

Re-irradiation for recurrent gliomas : Treatment outcomes and prognostic factors. / Lee, Jeongshim; Cho, Jaeho; Chang, Jong Hee; Suh, Chang Ok.

In: Yonsei medical journal, Vol. 57, No. 4, 07.2016, p. 824-830.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Re-irradiation for recurrent gliomas

T2 - Treatment outcomes and prognostic factors

AU - Lee, Jeongshim

AU - Cho, Jaeho

AU - Chang, Jong Hee

AU - Suh, Chang Ok

PY - 2016/7

Y1 - 2016/7

N2 - Purpose: The aim of this study was to evaluate the efficacy of re-irradiation in patients with recurrent gliomas and to identify subgroups for whom re-irradiation for recurrent gliomas is most beneficial. Materials and Methods: We retrospectively reviewed 36 patients with recurrent or progressive gliomas who received re-irradiation between January 1996 and December 2011. Re-irradiation was offered to recurrent glioma patients with good performance or at least 6 months had passed after initial radiotherapy (RT), with few exceptions. Results: Median doses of re-irradiation and initial RT were 45.0 Gy and 59.4 Gy, respectively. The median time interval between initial RT and re-irradiation was 30.5 months. Median overall survival (OS) and the 12-month OS rate were 11 months and 41.7%, respectively. In univariate analysis, Karnofsky performance status (KPS) ≥70 (p<0.001), re-irradiation dose ≥45 Gy (p=0.040), and longer time interval between initial RT and re-irradiation (p=0.040) were associated with improved OS. In multivariate analysis, KPS (p=0.030) and length of time interval between initial RT and re-irradiation (p=0.048) were important predictors of OS. A radiographically suspected mixture of radiation necrosis and progression after re-irradiation was seen in 5 patients. Conclusion: Re-irradiation in conjunction with surgery could be a salvage treatment for selected recurrent glioma patients with good performance status and recurrence over a long time.

AB - Purpose: The aim of this study was to evaluate the efficacy of re-irradiation in patients with recurrent gliomas and to identify subgroups for whom re-irradiation for recurrent gliomas is most beneficial. Materials and Methods: We retrospectively reviewed 36 patients with recurrent or progressive gliomas who received re-irradiation between January 1996 and December 2011. Re-irradiation was offered to recurrent glioma patients with good performance or at least 6 months had passed after initial radiotherapy (RT), with few exceptions. Results: Median doses of re-irradiation and initial RT were 45.0 Gy and 59.4 Gy, respectively. The median time interval between initial RT and re-irradiation was 30.5 months. Median overall survival (OS) and the 12-month OS rate were 11 months and 41.7%, respectively. In univariate analysis, Karnofsky performance status (KPS) ≥70 (p<0.001), re-irradiation dose ≥45 Gy (p=0.040), and longer time interval between initial RT and re-irradiation (p=0.040) were associated with improved OS. In multivariate analysis, KPS (p=0.030) and length of time interval between initial RT and re-irradiation (p=0.048) were important predictors of OS. A radiographically suspected mixture of radiation necrosis and progression after re-irradiation was seen in 5 patients. Conclusion: Re-irradiation in conjunction with surgery could be a salvage treatment for selected recurrent glioma patients with good performance status and recurrence over a long time.

UR - http://www.scopus.com/inward/record.url?scp=84969247769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969247769&partnerID=8YFLogxK

U2 - 10.3349/ymj.2016.57.4.824

DO - 10.3349/ymj.2016.57.4.824

M3 - Article

C2 - 27189273

AN - SCOPUS:84969247769

VL - 57

SP - 824

EP - 830

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 4

ER -